Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Work In Process (2022 - 2024)

Atara Biotherapeutics (ATRA) has disclosed Work In Process for 3 consecutive years, with $9.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Work In Process rose 31.47% year-over-year to $9.7 million, compared with a TTM value of $9.7 million through Dec 2024, up 31.47%, and an annual FY2024 reading of $9.7 million, up 31.47% over the prior year.
  • Work In Process was $9.7 million for Q4 2024 at Atara Biotherapeutics, down from $12.3 million in the prior quarter.
  • Across five years, Work In Process topped out at $15.1 million in Q2 2024 and bottomed at $372000.0 in Q4 2022.
  • Average Work In Process over 3 years is $7.8 million, with a median of $7.4 million recorded in 2023.
  • The sharpest move saw Work In Process soared 1881.45% in 2023, then surged 31.47% in 2024.
  • Year by year, Work In Process stood at $372000.0 in 2022, then skyrocketed by 1881.45% to $7.4 million in 2023, then soared by 31.47% to $9.7 million in 2024.
  • Business Quant data shows Work In Process for ATRA at $9.7 million in Q4 2024, $12.3 million in Q3 2024, and $15.1 million in Q2 2024.